Opioid Use Disorder Clinical Trial Landscape
Data updated: May 20, 2026
423 clinical trials tracked since 2008
Opioid Use Disorder is being studied across 423 clinical trials registered since 2008, with 129 programs currently active. The competitive pipeline includes 29 active Phase 3 trials, 51 active Phase 2 trials, and 24 active Phase 1 trials. Top industry sponsors include Go Medical Industries Pty Ltd, Akyso Therapeutics, LLC, Eli Lilly.
129 active
/
423 total (since 2008)
24
Phase 1 Active
96 total
51
Phase 2 Active
151 total
29
Phase 3 Active
90 total
38
Phase 4 Active
135 total
Top Industry Sponsors
Sorted by active Active Done Failed
Go Medical Industries Pty Ltd 1 2 0
Akyso Therapeutics, LLC 1 1 0
Eli Lilly 1 0 0
Sonara Health 1 0 0
Boehringer Ingelheim 1 0 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT04408313 ACTIVE NOT RECRUITING
Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail
Friends Research Institute, Inc. n=240
NCT05058287 RECRUITING
Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression
Hospital for Special Surgery, New York n=150
NCT06033599 RECRUITING
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
Rutgers, The State University of New Jersey n=420
NCT07524738 ACTIVE NOT RECRUITING
Telemedicine XR-B for Individuals in Jail
Friends Research Institute, Inc. n=30
NCT03823534 RECRUITING
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University n=60
+ 85 more Phase 3 trials — see full database below
Opioid Use Disorder — Trials Started by Year (last 10 years)
2016 13
2017 16
2018 29
2019 41
2020 42
2021 49
2022 35
2023 35
2024 35
2025 33
2026 24
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Go Medical Industries Pty Ltd 3
Akyso Therapeutics, LLC 2
Eli Lilly 1
Sonara Health 1
Boehringer Ingelheim 1
Inventage Lab., Inc. 1
Boulder Care 1
Proniras Corporation 1
Filament Health Corp. 1
Evon Medics LLC 1
Active Trials by Phase
Phase 1 24
Phase 2 51
Phase 3 29
Phase 4 38
Enrollment Size Distribution
1-50 184
51-200 143
201-500 49
501-1k 13
1k+ 7
All Industry Sponsors
Sorted by active Active Done Failed
Go Medical Industries Pty Ltd 1 2 0
Akyso Therapeutics, LLC 1 1 0
Eli Lilly 1 0 0
Sonara Health 1 0 0
Boehringer Ingelheim 1 0 0
Inventage Lab., Inc. 1 0 0
Boulder Care 1 0 0
Proniras Corporation 1 0 0
Filament Health Corp. 1 0 0
Evon Medics LLC 1 0 0
Indivior Inc. 0 20 0
USWM, LLC (dba US WorldMeds) 0 4 1
Braeburn Pharmaceuticals 0 4 0
AstraZeneca 0 2 1
Astellas Pharma Global Development, Inc. 0 2 1
NCT04408313 ACTIVE NOT RECRUITING
Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail
Friends Research Institute, Inc. n=240
NCT05058287 RECRUITING
Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression
Hospital for Special Surgery, New York n=150
NCT06033599 RECRUITING
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
Rutgers, The State University of New Jersey n=420
NCT07524738 ACTIVE NOT RECRUITING
Telemedicine XR-B for Individuals in Jail
Friends Research Institute, Inc. n=30
NCT03823534 RECRUITING
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University n=60
NCT04452344 ACTIVE NOT RECRUITING
Opioid Analgesic Reduction Study
Rutgers, The State University of New Jersey n=1,815
NCT05834478 RECRUITING
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Emory University n=103
NCT06077422 ENROLLING BY INVITATION
Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain
Rutgers, The State University of New Jersey n=150
NCT07148206 NOT YET RECRUITING
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Montefiore Medical Center n=40
NCT05459402 RECRUITING
Divided or Single Exposure (DOSE) Study
University of Maryland, Baltimore n=150
NCT07361432 NOT YET RECRUITING
Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine
VA Office of Research and Development n=250
NCT07296770 NOT YET RECRUITING
An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service
University of California, San Francisco n=126
NCT05766631 ACTIVE NOT RECRUITING
Treating Polysubstance Use Using a Novel Digital Technology
Friends Research Institute, Inc. n=240
NCT06940674 RECRUITING
Adjunctive Cannabidiol for Recovery From Opioid Study
Icahn School of Medicine at Mount Sinai n=450
NCT06316830 RECRUITING
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
Rhode Island Hospital n=250
NCT05589181 RECRUITING
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
Rutgers, The State University of New Jersey n=140
NCT05790252 RECRUITING
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
Washington University School of Medicine n=40
NCT06032559 RECRUITING
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
Rutgers, The State University of New Jersey n=450
NCT04893525 RECRUITING
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
University of British Columbia n=658
NCT05011266 RECRUITING
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
New York State Psychiatric Institute n=180
NCT06494904 RECRUITING
Standard Versus High Dose ED-Initiated Buprenorphine Induction
Yale University n=360
NCT04365920 ACTIVE NOT RECRUITING
Recovery Management Checkups for Opioid Use Disorder Experiment
Chestnut Health Systems n=455
NCT06089707 RECRUITING
Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
Johns Hopkins University n=25
NCT05283980 ACTIVE NOT RECRUITING
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
Beth Israel Deaconess Medical Center n=62
NCT05120076 RECRUITING
Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Periacetabular Osteotomy
Balgrist University Hospital n=60
NCT03345173 ACTIVE NOT RECRUITING
Facilitating Rapid Naltrexone Initiation
New York State Psychiatric Institute n=100
NCT07590752 RECRUITING
"Dexa vs Dexmedetomidine With Bupivacaine in TAP Block for Laparotomy Analgesia
Sahiwal medical college sahiwal n=96
NCT05597878 SUSPENDED
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
Wake Forest University Health Sciences n=100
NCT04655339 WITHDRAWN
Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids
Baylor Research Institute
NCT03616236 SUSPENDED
Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment
Friends Research Institute, Inc. n=320
NCT05153785 COMPLETED
Perioperative Intravenous Lidocaine in Liver Surgery
Lund University Hospital n=124
NCT07092475 WITHDRAWN
The Impact of Intraoperative Methadone on Postoperative Opioid Use
University of Utah
NCT04122196 COMPLETED
Perioperative Pregabalin in Ureteroscopy
University of Missouri-Columbia n=118
NCT04759703 TERMINATED
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
Massachusetts General Hospital n=75
NCT04588389 TERMINATED
Comparison of Quadratus Lumborum Block Types
University of Massachusetts, Worcester n=9
NCT05386069 COMPLETED
Does a Non-Opioid Multimodal Pain (NOMO) Protocol Decrease Narcotic Use
Prisma Health-Upstate n=10
NCT04081545 COMPLETED
Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery
Christine Oryhan n=181
NCT06522633 COMPLETED
Esophageal Dysfunction Associated With Opioids: Clinical Response and Manometric Findings After Opioid Discontinuation
Hospital Clinic of Barcelona n=20
NCT03929640 TERMINATED
Management Of Pain After Cesarean Trial
Milton S. Hershey Medical Center n=49
NCT04296396 COMPLETED
Opioid Prescription After Cesarean Trial
The George Washington University Biostatistics Center n=5,521
NCT04610398 COMPLETED
Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy
Balgrist University Hospital n=60
NCT04556552 COMPLETED
Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Emory University n=20
NCT01843751 COMPLETED
Dane County Drug Court Study for Addicted Offenders
University of Wisconsin, Madison n=24
NCT01082679 COMPLETED
Treatment for Opioid Dependent Offenders
University of Wisconsin, Madison n=16
NCT04622813 COMPLETED
Nonopioid Analgesics and Cholecystectomy
American University of Beirut Medical Center n=90
NCT02483468 COMPLETED
The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain
Medical University of South Carolina n=160
NCT03232346 COMPLETED
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
New York State Psychiatric Institute n=11
NCT04517110 TERMINATED
Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery
Hamilton Health Sciences Corporation n=17
NCT02696096 COMPLETED
Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Butler Hospital n=21
NCT04910165 COMPLETED
Exparel Use in Adductor Canal Block After Total Knee Arthroplasty
St. Luke's Hospital, Pennsylvania n=100
NCT03818399 TERMINATED
Virginia Opioid Overdose Treatment InitiatVE
Virginia Commonwealth University n=19
NCT03275350 COMPLETED
Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
Oregon Health and Science University n=114
NCT01863186 COMPLETED
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
USWM, LLC (dba US WorldMeds) n=603
NCT04246541 COMPLETED
Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery
University Hospitals Cleveland Medical Center n=48
NCT03113409 TERMINATED
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
New York State Psychiatric Institute n=10
NCT03508830 COMPLETED
Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial
University of California, San Francisco n=91
NCT03805386 COMPLETED
Patient-Directed Postoperative Opioid Prescribing for Gynecologic Surgery
Mayo Clinic n=65
NCT04523792 WITHDRAWN
Virginia Opioid Treatment-Emergency Department
Virginia Commonwealth University
NCT03169816 COMPLETED
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
New York State Psychiatric Institute n=60
NCT04197570 COMPLETED
Opioid-free Anesthesia for Open Cardiac Surgery: A Prospective Randomized Controlled Trial
Benaroya Research Institute n=9
NCT02672111 COMPLETED
Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
Braeburn Pharmaceuticals n=228
NCT02294253 COMPLETED
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
New York State Psychiatric Institute n=30
NCT02110264 COMPLETED
Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
University of California, Los Angeles n=151
NCT02651584 COMPLETED
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Braeburn Pharmaceuticals n=428
NCT02502175 COMPLETED
Comparing Opium Tincture (OT) With Methadone for Medication-assisted Treatment of Opioid Use Disorder
University of British Columbia n=204
NCT01908062 COMPLETED
Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
Oregon Health and Science University n=51
NCT02537574 COMPLETED
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
Alkermes, Inc. n=380
NCT02696434 COMPLETED
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
Alkermes, Inc. n=101
NCT02180659 COMPLETED
A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
Titan Pharmaceuticals n=177
NCT00768482 TERMINATED
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
Titan Pharmaceuticals n=9
NCT01717963 COMPLETED
Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
University of Oslo n=166
NCT00476242 COMPLETED
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
New York State Psychiatric Institute n=82
NCT01024335 COMPLETED
Dronabinol Naltrexone Treatment for Opioid Dependence
New York State Psychiatric Institute n=60
NCT02510014 COMPLETED
Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder
Indivior Inc. n=775
NCT02357901 COMPLETED
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
Indivior Inc. n=665
NCT03365817 COMPLETED
Cognitive Function and Addiction Under Opioid Tapering
Rigshospitalet, Denmark n=75
NCT01908842 COMPLETED
Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
Orexo AB n=759
NCT01447212 COMPLETED
Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)
University of British Columbia n=202
NCT01052662 COMPLETED
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
University of Massachusetts, Worcester n=87
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only